Fabry disease is a rare inherited condition in which a missing or defective enzyme allows certain fatty molecules to build up inside cells throughout the body, including the kidneys and heart. Even when patients receive the best available treatments, many continue to spill excess protein into their urine, a sign that kidney filtration is still being stressed. That persistent protein loss, called residual proteinuria, is one of the strongest predictors of how quickly kidney function will decline.
A recent proof-of-concept study published in a nephrology journal asked whether adding a dual GIP and GLP-1 receptor agonist peptide to existing therapy could push that residual proteinuria lower. The peptide in question, tirzepatide, works by activating two hormone receptors at once: one for glucose-dependent insulinotropic polypeptide (GIP) and one for glucagon-like peptide-1 (GLP-1). Researchers were interested not in its weight-loss properties per se, but in its reported anti-inflammatory, salt-excreting, and anti-scarring effects on tissues.
The study was small, enrolling only 15 overweight adults with Fabry disease who had no diabetes but did have stubborn proteinuria despite being on maximal approved kidney-protective medications. Over six months, the researchers tracked changes in urine protein levels, kidney filtration rate, body weight, and heart stress markers.
Background on the two receptor targets
GLP-1 is a hormone released from the gut after eating. It signals the pancreas to release insulin in a glucose-dependent way, but it also acts on receptors found in the kidneys, blood vessels, and heart. Research over the past decade has linked GLP-1 receptor activation to reduced inflammation, lower blood pressure inside the kidney's filtering units, and slower scarring of kidney tissue.
GIP is a second gut hormone that works alongside GLP-1 in blood sugar regulation. Its receptors are also expressed outside the gut, including in fat tissue and possibly the kidney. The dual agonist approach, hitting both receptors at once, was designed to amplify metabolic effects, but researchers have begun exploring whether those combined signals also carry direct organ-protective properties that go beyond glucose and weight.
Why Fabry disease is a relevant test case
In Fabry disease, fatty lipid deposits accumulate in the cells lining the kidney's tiny blood vessels and filtering structures. Over time this triggers chronic low-grade inflammation and fibrosis, the same two pathways that GIP and GLP-1 signaling appear to counteract in other contexts. Standard care involves enzyme replacement therapy or a pharmacological chaperone to reduce lipid buildup, combined with drugs that block the renin-angiotensin system to lower pressure on the kidneys. The problem is that even with all of those tools in place, a meaningful number of patients retain proteinuria above the threshold considered high-risk for progression.
The study authors framed their question specifically around that treatment gap. They were not trying to replace existing therapy but to test whether the dual receptor agonist could add a complementary, multi-pathway protective effect on top of what patients were already receiving.
Study design and patient characteristics
This was a prospective observational study described by the authors as a proof-of-concept investigation, meaning it was designed to generate preliminary signals rather than definitive conclusions. Fifteen Fabry patients were enrolled. All had 24-hour urine protein levels of at least 0.5 grams despite being on stable disease-specific therapy and the maximum tolerated dose of renin-angiotensin system blocking medication. None had diabetes. All were overweight, with average body-mass index just above 29 at the start.
The primary thing researchers wanted to measure was the change in 24-hour urine protein from baseline to month six. Secondary measures included estimated glomerular filtration rate, which reflects how well the kidneys filter waste; BMI; and two cardiac biomarkers called NT-proBNP and high-sensitivity troponin T, both of which rise when heart muscle is under stress.
Key measurements at six months
The headline finding was a 68.9 percent reduction in 24-hour proteinuria, falling from an average of roughly 1.11 grams at baseline to 0.35 grams by month six. That reduction was statistically significant as early as month one and continued to deepen through the full observation period. Two-thirds of participants, exactly 10 of the 15 patients, reached the commonly cited lower-risk threshold of below 0.5 grams of protein per day.
Kidney filtration rate remained essentially unchanged across the six months, with no statistically significant shift. This matters because a large drop in filtration rate would suggest the peptide was reducing protein loss by simply cutting blood flow to the kidney, an undesirable trade-off. The stable filtration rate points toward a different mechanism, possibly reduced inflammation or lower pressure inside the kidney's microscopic filtering structures.
Body weight fell substantially. Average BMI dropped from 29.0 at baseline to 24.2 at month six. The researchers acknowledged this weight reduction and discussed whether it explained the proteinuria changes. They could not fully separate the two effects in a study this size, but they noted that the speed and magnitude of the protein reduction appeared to exceed what weight loss alone typically produces in similar populations.
The two cardiac biomarkers also moved. NT-proBNP fell by 33.3 percent and high-sensitivity troponin T fell by 14.3 percent. Both changes were statistically significant. Importantly, standard echocardiographic measurements of heart structure did not change, which the authors described as consistent with early modulation of myocardial stress signals rather than any structural remodeling detectable over six months.
Safety and tolerability observations
The abstract reports mild gastrointestinal symptoms during the initial dose titration phase, a pattern consistent with other studies involving GLP-1 pathway peptides. No participants discontinued treatment. The authors characterize the tolerability profile as acceptable in this non-diabetic Fabry cohort, though they note the study was not powered to detect rare adverse events.
Context and limitations
The authors frame their findings as supportive of a multi-pathway approach to kidney protection in Fabry disease, one that extends beyond reducing lipid substrate and blocking the renin-angiotensin system. They use careful language, describing the results as an association rather than a proven causal effect, and call explicitly for larger controlled trials to confirm what this small cohort suggested.
There are meaningful limitations to acknowledge. Fifteen patients is a very small sample. The study had no control group, meaning there is no direct comparison to patients who continued existing therapy without the add-on peptide. The observation period was six months, which is too short to know whether the proteinuria reduction translates to slower long-term kidney function decline. The study also cannot cleanly separate the direct organ effects of dual GIP and GLP-1 receptor activation from the effects of weight loss itself.
Still, for researchers studying the intersection of incretin biology and rare kidney disease, the data provide an early signal worth investigating further. The combination of a significant proteinuria reduction, stable filtration rate, and falling cardiac stress markers in a population that had already exhausted standard nephroprotective options is, at minimum, a hypothesis worth testing in a rigorous randomized trial.
